Related Experiment Video
Updated: Apr 16, 2026
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
BRAF V600E mutation-specific antibody: A review
Lauren L Ritterhouse1, Justine A Barletta1
1Department of Pathology, Brigham and Women׳s Hospital, Harvard Medical School, 75 Francis St, Boston, Massachusetts 02115.
Abstract:
The significance of BRAF mutations in neoplasia was first recognized in 2002 when mutations were discovered in a broad range of cancers. Numerous subsequent studies expanded our understanding of BRAF V600E as a critical diagnostic, prognostic, and predictive biomarker in many cancers. Additionally, the advent of small-molecule inhibitors of BRAF V600E rendered assessment of BRAF mutation status essential in tumors such as melanoma. In clinical practice, evaluation of BRAF mutation status has routinely been performed by DNA-based assays utilizing polymerase chain reaction (PCR). However, molecular testing is not available at many hospitals since it is time-consuming, expensive, and requires expertise in molecular techniques. The first BRAF V600E-specific antibody was reported in 2011 (clone VE1). A purified version of this antibody as well as a second monoclonal antibody targeted to BRAF V600E is now commercially available. In this review, clinicopathologic characteristics associated with BRAF-mutant tumors will be highlighted, and the prognostic and predictive implications of a BRAF V600E mutation will be discussed with a focus on melanoma, thyroid carcinoma and colorectal carcinoma. Additionally, we will review the correlation between immunohistochemistry and molecular results and deliberate how BRAF immunohistochemistry might be utilized in the evaluation of these tumors.
Insights
BRAF V600E mutations are key biomarkers in many cancers, driving diagnosis and treatment. Immunohistochemistry offers a practical alternative to molecular testing for BRAF V600E evaluation in tumors.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Biomarkers
Background:
- BRAF mutations, particularly V600E, are significant in neoplasia, identified in various cancers since 2002.
- BRAF V600E serves as a critical diagnostic, prognostic, and predictive biomarker, essential for targeted therapies like small-molecule inhibitors in melanoma.
- Current BRAF mutation testing relies on DNA-based polymerase chain reaction (PCR) assays, which are often time-consuming, costly, and require specialized expertise, limiting accessibility.
Purpose of the Study:
- To review clinicopathologic features of BRAF-mutant tumors.
- To discuss the prognostic and predictive implications of BRAF V600E mutations in melanoma, thyroid, and colorectal carcinomas.
- To evaluate the utility of BRAF V600E immunohistochemistry (IHC) as a diagnostic tool and its correlation with molecular testing.
Main Methods:
- Review of existing literature on BRAF mutations and their clinical significance.
- Analysis of clinicopathologic characteristics associated with BRAF-mutant tumors.
- Discussion of BRAF V600E-specific antibodies (e.g., clone VE1) and their application in immunohistochemistry.
Main Results:
- BRAF V600E mutations are established biomarkers with significant prognostic and predictive value in several cancer types.
- Immunohistochemistry using BRAF V600E-specific antibodies provides a viable alternative to molecular testing.
- Commercial availability of BRAF V600E antibodies facilitates broader clinical application.
Conclusions:
- BRAF V600E mutation status is crucial for cancer patient management, particularly in melanoma, thyroid, and colorectal cancers.
- BRAF immunohistochemistry presents a valuable, accessible method for assessing BRAF V600E mutation status in clinical settings.
- Further research can optimize the integration of BRAF IHC into routine tumor evaluation workflows.
More Related Videos
08:09Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016